Navigation Links
Cellular Dynamics International's (CDI) Human Induced Pluripotent Stem Cell (iPSC) Technology Named the Gold Winner in The Wall Street Journal 2011 Technology Innovation Awards

MADISON, Wis., Oct. 17, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced that it was named as the overall Gold winner in The Wall Street Journal Technology Innovation Awards.

The Wall Street Journal 2011 Technology Innovation Awards are determined by a panel of independent judges who evaluated significant innovations that occurred in 2010.  Six-hundred-five applicants competed for the award in 16 categories.  Of these, the panel chose 35 winners and runners-up.

"Medical research has been challenged by the lack of access to a consistent supply of human cells, such as heart or brain cells," said Dr. James Thomson, CDI founder and chief scientific officer.  "Research today employs proxies, such as animal cells, tumor cell lines or cadaveric tissue, none of which truly reflect human biology.  I founded CDI based on my desire to make pluripotent stem cells and human tissue cells widely available to accelerate discoveries in human health and biological research. CDI's production technology and capacity provide this access, enabling us to manufacture human material from anyone. CDI has overcome the scalability challenges, mass producing industrial quantities of human cells in high quality and purity."

CDI has developed a proprietary manufacturing process in which cells isolated from a doctor's office standard blood draw from virtually anyone can be reprogrammed into that individual's personal pluripotent stem cell line.  CDI can then differentiate these stem cells into any cell type in the human body in industrial quantity, quality and purity so that scientists have a consistent supply of human cells from specific individuals.  Two human cell products, iCell® Cardiomyocytes (heart muscle cells) and iCell Endothelial Cells (blood vessel cells), have been launched over the past two years, with neurons and liver cells already available in early access collaborations with researchers worldwide.

"CDI is the first company to utilize stem cell technology to manufacture the vast quantities of high quality stem cells and tissue cells required to better understand human biology, revolutionize the drug discovery process, and develop cell-based therapies to treat human diseases," said Robert Palay, chairman of the board and CDI chief executive officer.  "We are honored that The Wall Street Journal's panel of independent judges recognized our company as a breakthrough innovator in human medicine and biotechnology."

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration.  CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual's stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw.  CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison.  CDI's facilities are located in Madison, Wisconsin. See

SOURCE Cellular Dynamics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Profiler at the cellular level
2. Cellular Dynamics Launches Innovative Research Grant Program
3. Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs
4. Medical College of Wisconsin and Cellular Dynamics Awarded NHLBI Grant Using Human Induced Pluripotent Stem Cells
5. Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma
6. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
7. Cellular Dynamics Licenses Technology From ViaCyte
8. Cellular Dynamics International Scientists Report on Efficient Method to Produce Footprint-Free Induced Pluripotent Stem Cells (iPSCs) Under Feeder-Free Conditions
9. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
10. Cellular Dynamics International to Present at 29th Annual JPMorgan Healthcare Conference
11. Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinsons Disease
Post Your Comments:
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):